Home » Newsletters » BioWorld Science

BioWorld Science

July 8, 2010

View Archived Issues

Scientists present tissue-specific anti-inflammatory NF-kappaB inhibitor LSC-1

New dual CFTR activators/deltaF508-CFTR correctors claimed

Auspex Pharmaceuticals describes deuterated DHFR inhibitors

Best response of stable disease seen in phase I BI-811283 trial in solid tumors

Phase I data reported on PCI-32765 in non-Hodgkin's lymphoma

Enzastaurin shows potential in phase II follicular lymphoma trial

Perseid receives milestone payment from Astellas for CTLA-4-Ig program

Cortex Pharma receives MJFF grant to identify PD therapeutics

CNTO-888 well tolerated in patients with advanced solid tumors

First-in-human data presented on oncolytic agent MNRP-1685A

Aastrom seeks SPA for phase III program of vascular repair cells in CLI

Chewable Lipitor obtains European approval for use in children

FDA approves Kamada's Glassia for alpha-1-antitrypsin deficiency

FDA expands label of Infergen in chronic hepatitis C

Molecular Templates and ImClone enter oncology research collaboration

Merck Frosst claims new cathepsin B inhibitors

Leo Pharma describes new PDE4 inhibitors for dermatological disorders

New tyrosine kinase inhibitors claimed by Merck KGaA

Dosing initiated in phase I trial of ALN-TTR01 for TTR-mediated amyloidosis

FDA grants fast track and orphan drug designations to BB3

Phase IIb gabapentin prodrug trial in migraine does not meet primary endpoint

TB Alliance and DNDi to investigate nitroimidazoles for neglected diseases

Dynavax commences phase I trial of universal flu vaccine

BioMimetic reports on Augment bone graft trials

NOXXON to begin phase Ib trial of NOX-E36 for diabetes

FDA grants orphan drug status to SBC-102 for lysosomal acid lipase deficiency

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...